MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR

Compounds of Formula (I), (I), wherein values of Y1, Y2, X, R1, R2, R3, R4 substitudes and k, r, m, n, p, q variabels are provided in the claims, pharmaceutically acceptable salt and deuterated derivative thereof, and pharmaceutical usage therefor the treatment of mucoviscidose. s Table: 9

Saved in:
Bibliographic Details
Main Authors KHATUYA, Haripada, ABELA, Alexander, Russell, JOSHI, Pramod Virupax, HADIDA RUAH, Sara Sabina, MCCARTNEY, Jason, CLEVELAND, Thomas, ANDRESON, Corey, MCAULEY-AOKI, Rachel, ALCACIO, Timothy, HUGHES, Robert M, TERMIN, Andreas, P, KRENITSKY, Paul John, BAEK, Minson, ZHOU, Jinglan, BUSCH, Brett, Bradley, VAN GOOR, Fredrick, PARASELLI, Prasuna, MILLER, Mark Thomas, Ali KESHAVARZ-SHOKRI, Ali, GROOTENHUIS, Peter, FRIEMAN, Bryan A, UY, Johnny, MELILLO, Vito, PIERRE, Fabrice, Jean Denis, ZHANG, Beili, SIESEL, David, Andrew
Format Patent
LanguageEnglish
Published 10.12.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Compounds of Formula (I), (I), wherein values of Y1, Y2, X, R1, R2, R3, R4 substitudes and k, r, m, n, p, q variabels are provided in the claims, pharmaceutically acceptable salt and deuterated derivative thereof, and pharmaceutical usage therefor the treatment of mucoviscidose. s Table: 9
Bibliography:Application Number: GE2017AP15057